USE OF USTEKINUMAB IN REFRACTORY PATIENTS OF PSORIASIS

M.D. GIL-SIERRA[1], E. RIOS-SANCHEZ[1], M.D.P. BRICEÑO-CASADO[1], S. FENIX-CABALLERO[1], C. MARTINEZ-DIAZ[1], C. PALOMO-PALOMO[1], E.J. ALEGRE-DEL REY[1], J. DIAZ-NAVARRO[1], J.F. LOPEZ-VALLEJO[1], M. CAMEAN-CASTILLO[1], J.M. BORRERO-RUBIO[1].

[1]HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN.

D05 - Antipsoriatics

4CPS-034

BACKGROUND

Ustekinumab is indicated for moderate to **severe psoriasis** (msPs) in patients who have had an inadequate response to systemic treatments.

PURPOSE

To assess **effectiveness** and **safety** of ustekinumab in our hospital patients with msPs **refractory** to tumor necrosis factor inhibitors (anti-TNFα).

MATERIAL AND METHODS

Descriptive retrospective study from January-2010 to September-2018

Patients → msPs had previously been treated with ≥**2 anti-TNFα** and received ustekinumab

DATA: Farmatools® application and digital clinical history

- Age
- Gender
- Previous treatment
- Therapy duration
- Treatment regimen
- PASI

Treatment regimen

- Weight ≤100kg: ustekinumab 45 mg at week 0, 4 and 16, followed 45 mg every 12 weeks
- Weight >100kg: ustekinumab 90 mg



SAFETY → Adverse reactions (**RA**)

RESULTS

- **Patients**: 36.
- **Gender**: 22 (61.1%) men, 14 (38.9%) women.
- **Mean age**: 47.2 (24-78) years.
- **Mean therapy duration:** 30.7 (6-85) months.
- **Treatment regimen:** 34 (94.4%) patients received ustekinumab 45 mg and 2 (5.6%) ustekinumab 90 mg.
- **AR:** none.



PASI
PASI≥12: 29 (80.5%)
PASI 6: 2 (5.6%)
PASI 4: 2 (5.6%)
PASI 2: 3 (8.3%)

PASI 90	PASI 75
24 (66.7%)	7 (19.4%)

PASI 90	PASI 75
24 (66.7%)	7 (19.4%)

Withdrawal treatment:
1 for pregnancy

PASI 90	PASI 75
20 (57.1%)	7 (20%)



CONCLUSION

1. Ustekinumab was an **effective** treatment in more than half of our study patients with msPs refractory to ≥2 anti-TNFα, showing an response **maintained for long periods** of time (96 weeks).
2. No patients recorded AR, so ustekinumab was **safe** in our hospital patients.
3. Studies with more sample size and duration are necessary to assess efectiveness and security of ustekinumab -main **limitation** of our research was limited **number of patients**-.

http://www.eahp.eu/24-4CPS-034